Home
CYBN
CYBN News

Latest Cybin Inc. (CYBN) News on October 14, 2025

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Business Wire

a month ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Business Wire

3 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development

Insider Monkey

4 months ago

Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development

Trump Trade: President said to weigh possible U.S. strike against Iran

TipRanks

4 months ago

Trump Trade: President said to weigh possible U.S. strike against Iran

Psychedelic advocates hopeful Trump administration will support space, STAT says

TipRanks

4 months ago

Psychedelic advocates hopeful Trump administration will support space, STAT says

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Newsfile

4 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Business Wire

4 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Business Wire

4 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Business Wire

4 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Business Wire

4 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Business Wire

5 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Business Wire

5 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Business Wire

5 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Business Wire

5 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

TipRanks

5 months ago

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Business Wire

5 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Business Wire

5 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Market Exclusive

6 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks

6 months ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Business Wire

6 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Business Wire

6 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks

7 months ago

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

TipRanks

7 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks

7 months ago

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

7 months ago

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Psychedelic: GH Research, Compass Pathways report earnings results

TipRanks

8 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet

Zacks

8 months ago

Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Business Wire

8 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade

Zacks

8 months ago

Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Business Wire

9 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Business Wire

9 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Business Wire

9 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Business Wire

10 months ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Business Wire

10 months ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Business Wire

a year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Business Wire

a year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Business Wire

a year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Business Wire

a year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Business Wire

a year ago

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Business Wire

a year ago

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Business Wire

a year ago

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Business Wire

a year ago

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Business Wire

a year ago

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Cybin Announces Completion of Previously Announced Share Consolidation

Business Wire

a year ago

Cybin Announces Completion of Previously Announced Share Consolidation

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire

a year ago

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Business Wire

a year ago

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Business Wire

a year ago

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Business Wire

a year ago

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire

a year ago

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Newsfile

a year ago

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

What Makes Cybin Inc. (CYBN) a New Buy Stock

Zacks

a year ago

What Makes Cybin Inc. (CYBN) a New Buy Stock

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Business Wire

a year ago

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Business Wire

a year ago

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround

Zacks

a year ago

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

Business Wire

a year ago

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

Business Wire

a year ago

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Business Wire

a year ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

Business Wire

a year ago

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Business Wire

a year ago

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Business Wire

a year ago

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Business Wire

a year ago

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire

2 years ago

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Business Wire

2 years ago

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Business Wire

2 years ago

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Business Wire

2 years ago

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Business Wire

2 years ago

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Announces Oversubscribed Private Placement of U.S. $150 Million

Business Wire

2 years ago

Announces Oversubscribed Private Placement of U.S. $150 Million

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Business Wire

2 years ago

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

Business Wire

2 years ago

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

Business Wire

2 years ago

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Business Wire

2 years ago

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

Business Wire

2 years ago

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

Why Domo (DOMO) Shares Are Getting Obliterated Today

StockStory

2 years ago

Why Domo (DOMO) Shares Are Getting Obliterated Today

Business Wire

2 years ago

Putnam Investments Announces Distribution Rates for Closed-End Funds

Market Exclusive

2 years ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Is LSI Industries Inc. (NASDAQ:LYTS) Trading At A 44% Discount?

Simply Wall St.

2 years ago

Is LSI Industries Inc. (NASDAQ:LYTS) Trading At A 44% Discount?

Immersion Corporation (IMMR) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

2 years ago

Immersion Corporation (IMMR) Is a Trending Stock: Facts to Know Before Betting on It

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Business Wire

2 years ago

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

GuruFocus.com

2 years ago

Home Bancorp Inc (HBCP) Reports Q4 Earnings, Declares Dividend Amidst Economic Challenges

Home Bancorp (HBCP) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

2 years ago

Home Bancorp (HBCP) Reports Q4 Earnings: What Key Metrics Have to Say

Sinclair Announces Annual Diversity Scholarship Submission for 2024, Shaping the Future of Broadcasting

Business Wire

2 years ago

Sinclair Announces Annual Diversity Scholarship Submission for 2024, Shaping the Future of Broadcasting

Business Wire

2 years ago

Putnam Investments Announces 19(a) Notices for Closed-End Municipal Funds

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Zacks

2 years ago

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Business Wire

2 years ago

Luxfer Declares Quarterly Dividend

Business Wire

2 years ago

Franklin Limited Duration Income Trust ("FTF" or the "Fund") Announces Distribution

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

Zacks

2 years ago

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

Rigel Pharmaceuticals Provides Business Update

PR Newswire

2 years ago

Rigel Pharmaceuticals Provides Business Update

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Business Wire

2 years ago

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

National Bank Holdings Corporation Announces Date for 2023 Fourth Quarter Earnings Release

GlobeNewswire

2 years ago

National Bank Holdings Corporation Announces Date for 2023 Fourth Quarter Earnings Release

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Business Wire

2 years ago

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Is Now An Opportune Moment To Examine Luxfer Holdings PLC (NYSE:LXFR)?

Simply Wall St.

2 years ago

Is Now An Opportune Moment To Examine Luxfer Holdings PLC (NYSE:LXFR)?

Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc

GuruFocus.com

2 years ago

Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc

Nano Dimension Announces Record Fourth Quarter and Full Year 2023 Preliminary Results

GlobeNewswire

2 years ago

Nano Dimension Announces Record Fourth Quarter and Full Year 2023 Preliminary Results

Highland Global Allocation Fund Declares Monthly Distributions of $0.081 Per Share

PR Newswire

2 years ago

Highland Global Allocation Fund Declares Monthly Distributions of $0.081 Per Share

‘Time to Hit Buy,’ Says Jefferies About These 2 Timeshare Stocks

TipRanks

2 years ago

‘Time to Hit Buy,’ Says Jefferies About These 2 Timeshare Stocks

All You Need to Know About LINKBANCORP, Inc. (LNKB) Rating Upgrade to Strong Buy

Zacks

2 years ago

All You Need to Know About LINKBANCORP, Inc. (LNKB) Rating Upgrade to Strong Buy

Business Wire

2 years ago

Franklin Limited Duration Income Trust ("FTF" or the "Fund") Announces Notification of Sources of Distributions

TeraWulf Reports Fully Funded 7.9 EH/s and Future Expansion Plans

GlobeNewswire

2 years ago

TeraWulf Reports Fully Funded 7.9 EH/s and Future Expansion Plans

NaaS Won the "Best Listed Company at ESG Information Disclosure"

PR Newswire

2 years ago

NaaS Won the "Best Listed Company at ESG Information Disclosure"

Business Wire

2 years ago

Franklin Limited Duration Income Trust ("FTF") Announces Change to Managed Distribution Plan

Share on Social Networks: